Glucagon

This page shows the latest Glucagon news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk’s weight-loss drug recommended by NICE

The drug suppresses patients’ appetites by mimicking an intestinal hormone called glucagon-like peptide-1 (GLP-1), which is released after eating.

Novo Nordisk’s type 2 diabetes drug approved by FDA as first-line option

Initially approved by in the US in 2019, Rybelsus is the first and only analogue of the naturally occurring hormone glucagon-like peptide-1 (GLP-1) in pill form and is
Oramed’s oral insulin candidate fails to meet phase 3 targets

In addition to ORMD-0801, Oramed currently has an oral Glucagon-like Peptide 1 analog capsule, ORMD-0901, in clinical development.
Novo Nordisk growth takes a hit with China deal

Xultophy is a combination of insulin degludec and Novo’s glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, which it markets as Victoza.
Kriya Therapeutics raises $100m to further develop gene therapies with ‘broader applications’

a gene therapy designed to produce a glucagon-like peptide 1 (GLP-1) receptor agonist for type 2 diabetes and severe obesity – KT-A522.
Novo Nordisk launches late-stage study in Alzheimer’s disease

Semaglutide binds to and activate the glucagon-like peptide-1 (GLP-1) receptor to increase insulin secretion in type 2 diabetes patients.

More from news
Approximately 1 fully matching, plus 56 partially matching documents found.

Alzheimer’s: the search for a cure

Similar retrospective positive findings were recently published for the anti-diabetic, glucagon-like peptide-1 receptor agonist (GLP1-RA), which was also found to reduce neuroinflammation.
Sourcing R&D innovation: why pharma companies need to evolve their business models

Examples of this approach include developing statins for the treatment of dyslipidemia, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) for hypertension, and glucagon-like peptide 1
Cortellis Drugs to Watch in 2020 report

7. NovoNordisk’s Rybelsus is an oral once-daily formulation of semaglutide, a long-acting glucagon-like peptide (GLP)-1 analog.
Oral biologics delivery still elusive

In fact, diabetes is thought to be the single largest area for oral delivery of biologics, with a number of groups working on oral insulin as well as analogues of glucagon -
Deal Watch November 2015

Included in the package are three products: a weekly insulin, a fixed weekly dose combination of GLP-1-RA/insulin and efpeglenatide, a long acting glucagon like peptide-1 receptor agonist. ... Again this was a global deal (excluding South Korea and China)

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Early Access Program - Regulatory Affairs (EAP-RA): Highly competitive salary

Associate Director - Global Healthcare Consulting: £100,000 - £115,000 yearly

Add my company

Because health means everything...

Time to talk about health inequalities: Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
The speed of science and the pace of comms: Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
Improving cardiovascular disease care and awareness: Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...

Email:
Password: